Associated Papers
A covalent allosteric molecular glue suppresses NRF2-dependent cancer growth.
Roy N et al.
Cancer Discovery, 2025
PPIA dictates NRF2 stability to promote lung cancer progression.
Lu W et al.
Nature Communications, 2024
The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations.
Kulkarni A et al.
Oncotarget, 2021
33889302 (PubMed )
Supplement: oncotarget-12-791-s001.pdf
Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites.
Saigusa D et al.
Cancer Science, 2020
31828882 (PubMed )
Supplement: CAS-111-667-s002.xlsx › Table_S2
Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer.
MacLeod AK et al.
British Journal of Cancer, 2016
NCI-60 whole exome sequencing and pharmacological CellMiner analyses.
Reinhold WC et al.
Plos One, 2014
25032700 (PubMed )
Supplement: pone.0101670.s001.xlsx › Supplementary_Table_1
Select a paper to view details